Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Gane EJ, et al. Among authors: foster gr. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28802816 Clinical Trial.
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR; UK Amantadine Study Group. Caronia S, et al. Among authors: foster gr. J Hepatol. 2001 Oct;35(4):512-6. doi: 10.1016/s0168-8278(01)00140-4. J Hepatol. 2001. PMID: 11682036 Clinical Trial.
The way forward in HCV treatment--finding the right path.
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. Manns MP, et al. Among authors: foster gr. Nat Rev Drug Discov. 2007 Dec;6(12):991-1000. doi: 10.1038/nrd2411. Nat Rev Drug Discov. 2007. PMID: 18049473 Review.
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients.
Patel K, Thompson AJ, Chuang WL, Lee CM, Peng CY, Shanmuganathan G, Thongsawat S, Tanwandee T, Mahachai V, Pramoolsinsap C, Cho M, Han KH, Shah SR, Foster GR, Clark PJ, Pulkstenis E, Subramanian GM, McHutchison JG. Patel K, et al. Among authors: foster gr. J Gastroenterol Hepatol. 2011 Jul;26(7):1182-8. doi: 10.1111/j.1440-1746.2011.06722.x. J Gastroenterol Hepatol. 2011. PMID: 21410752 Clinical Trial.
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.
Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM, McHutchison JG, Sulkowski MS, Zeuzem S, Nelson DR. Shah SR, et al. Among authors: foster gr. Clin Gastroenterol Hepatol. 2011 Aug;9(8):688-93. doi: 10.1016/j.cgh.2011.04.029. Epub 2011 May 13. Clin Gastroenterol Hepatol. 2011. PMID: 21640198 Free PMC article. Clinical Trial.
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. Ramachandran P, et al. Among authors: foster gr. Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1. Aliment Pharmacol Ther. 2012. PMID: 22296568 Free article.
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; B2202 Study Team. Pianko S, et al. Among authors: foster gr. J Viral Hepat. 2012 Sep;19(9):623-34. doi: 10.1111/j.1365-2893.2012.01586.x. Epub 2012 Mar 21. J Viral Hepat. 2012. PMID: 22863266 Clinical Trial.
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK. Foster GR, et al. J Viral Hepat. 2013 Apr;20(4):e115-23. doi: 10.1111/jvh.12020. Epub 2013 Feb 14. J Viral Hepat. 2013. PMID: 23490379 Clinical Trial.
Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X, Freshwater D, Ryder S, Mills PR, Alexander GJ, Forton D, Foster GR. Shoeb D, et al. Among authors: foster gr. J Hepatol. 2014 Apr;60(4):699-705. doi: 10.1016/j.jhep.2013.11.011. Epub 2013 Nov 26. J Hepatol. 2014. PMID: 24291239 Clinical Trial.
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Zeuzem S, et al. N Engl J Med. 2014 May 22;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795201 Free article. Clinical Trial.
273 results